- Home
- DEO vs TAK Comparison
DEO vs TAK Comparison
Compare DEO & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DEO | TAK |
|---|---|---|
| Founded | 1886 | 1781 |
| Country | United Kingdom | Japan |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.6B | 55.5B |
| IPO Year | 2001 | 2007 |
Fundamental Metrics
Financial Performance| Metric | DEO | TAK |
|---|---|---|
| Price | $96.08 | $18.24 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $109.00 | N/A |
| AVG Volume (30 Days) | 1.3M | ★ 3.5M |
| Earning Date | 02-25-2026 | 05-13-2026 |
| Dividend Yield | ★ 4.18% | 3.24% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.65 | $0.16 |
| Revenue Next Year | N/A | $1.22 |
| P/E Ratio | $90.04 | ★ $41.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $72.45 | $12.99 |
| 52 Week High | $113.36 | $18.90 |
Technical Indicators
Market Signals| Indicator | DEO | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 64.37 | 64.71 |
| Support Level | $85.46 | $17.40 |
| Resistance Level | $97.63 | $18.74 |
| Average True Range (ATR) | 1.57 | 0.21 |
| MACD | -0.09 | 0.07 |
| Stochastic Oscillator | 89.77 | 85.45 |
Price Performance
Historical ComparisonAbout DEO Diageo plc
Formed in 1997 through the merger of Grand Metropolitan and Guinness, Diageo is the largest distiller globally by sales. Diageo acquired some of the Seagram assets in 2001, which gave it brands such as Captain Morgan rum and Crown Royal Canadian whisky. Since then, mergers and acquisitions have mostly been bolt-on in nature, plugging gaps in the company's product and geographic portfolio.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.